|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||582.75 - 594.00|
|52-week range||479.00 - 663.00|
|PE ratio (TTM)||40.50|
|Forward dividend & yield||2.00 (0.36%)|
|1y target est||N/A|
"The company is fairly valued at current market price. However, if Q4FY18 results are robust then we can expect a target of Rs 650 by FY19 end," says Akash Jain, Vice-president, Equity Research at Ajcon Global Services.
"The United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility from April 2, 2018 till April 13, 2018," Cipla said in a BSE filing.
The US Food and Drug Administration has recently completed its inspection of Cipla's Indore facility.
Cipla Ltd, India's fourth-largest drugmaker by revenue, said third-quarter net profit rose 7 percent on strong domestic sales, but fell short of analysts' estimates. Net profit attributable to shareholders ...
Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday. Drugmakers Lupin Ltd and ...
Mumbai, Aug 14 (IANS) Broadly positive global cues, coupled with healthy buying in consumer durables, metals and automobile stocks, lifted the key Indian equity indices from their five-week lows to trade ...
Cipla Ltd, India's fourth-largest drugmaker by sales, reported a 20 percent rise in quarterly profit, beating analysts' estimates, as higher sales in Europe and South Africa offset weakness in its key domestic market. Revenue from South Africa, Cipla's third largest market, rose 21 percent to 4.88 billion rupees ($76.03 million) compared with last year while Europe revenues climbed 33 percent to 1.58 billion rupees. India revenues fell 13 percent to 12.71 billion rupees, impacted by a nationwide tax reform.
Cipla Ltd (CIPL.NS), India's fifth-largest drugmaker by sales, plans to reduce investment in biosimilars to sharpen its focus on building a portfolio of high-margin respiratory products, the company's chief executive said on Thursday. It has put plans to build a biotech plant in South Africa, its third-largest market, on hold, and will soon start looking for partners for its existing biosimilars programme, CEO Umang Vohra said at a press conference. The move signals a shift in Cipla's strategy from just three years ago, when Chairman and founder Yusuf Hamied said the company aimed to replicate its success at launching cut-price AIDS drugs in Africa in 2001 with cheap biosimilars.